What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lumbar Degenerative Disc Disease
- Main trialPhase 3
- “The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.”In the company’s words, NCT05516992 on ClinicalTrials.gov
Other drugs for Lumbar Degenerative Disc Disease
- Rexlemestrocel-LMesoblast, Ltd. · Phase 3
- IDCTDiscGenics, Inc. · Phase 3
- MDT-0123Medtronic Spinal and Biologics · Phase 3
- ANPCASTEROGENE Biomedical Co. Ltd. · Phase 1/2
- BRTX-100BioRestorative Therapies · Phase 2
- CELZ-201-DDTCreative Medical Technology Holdings Inc · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 21 Mar 2025 | Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026